Evan S. Dellon, MD, MPH: Dupilumab Shows Promise Treating Eosinophilic Esophagitis


Research shows dupilumab remains effective in EoE for up to 2 years.

While many treatments may wane in effectiveness in patients with eosinophilic esophagitis (EoE), initial data shows dupilumab (Dupixent) could be beneficial at least up to 2 years for patients.

In data presented at the annual American College of Gastroenterology (2020) conference, researchers found the treatment significantly improved dysphagia and histological and endoscopic measures of EoE in patients.

"In Part A of the double-blind, placebo-controlled Phase 3 trial, the investigators examined 81 patients aged 12 years and older with active EoE. Each participant received 24 weeks of subcutaneous dupilumab 300 mg weekly or placebo.

Dupilumab also significantly normalized the expression of genes associated with type 2 inflammation, including genes associated with type 2 inflammatory cell responses, proinflammatory cytokine production, and mucins.

In addition, dupilumab normalized genes associated with eosinophils and mast cells by downregulating genes linked to eosinophil recruitment and genes encoding eosinophil and mast cell surface proteins, which are all dysregulated in the EoE transcriptome.

In an interview with HCPLive®, Evan Dellon, MD, MPH, professor of Medicine and Epidemiology, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, explained how dupilumab could be a top of the line treat for patients with EoE.

Recent Videos
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
HCPLive Five at ADA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.